{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:24:30Z","timestamp":1793363070032,"version":"4.5.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002363","name":"Brazilian Society of Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Brazilian Journal of Infectious Diseases"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.bjid.2025.104589","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T08:23:53Z","timestamp":1761121433000},"page":"104589","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Guideline for antimicrobial treatment of multidrug-resistant Gram-negative infections: practice recommendations of the Brazilian Society of Infectious Diseases"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5331-4837","authenticated-orcid":false,"given":"Alexandre Prehn","family":"Zavascki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4557-2662","authenticated-orcid":false,"given":"Alberto","family":"Chebabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2541-7884","authenticated-orcid":false,"given":"Clovis Arns","family":"Cunha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0640-5442","authenticated-orcid":false,"given":"Alexandre Rodrigues","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8732-8946","authenticated-orcid":false,"given":"Gabriel Trova","family":"Cuba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4946-911X","authenticated-orcid":false,"given":"Daniel Wagner C.L.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0913-768X","authenticated-orcid":false,"given":"Ana Cristina","family":"Gales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bjid.2025.104589_bib0001","unstructured":"ANVISA. Boletim Seguran\u00e7a do Paciente e Qualidade em Servi\u00e7os de Sa\u00fade n\u00ba 31 \u2013 Avalia\u00e7\u00e3o Nacional dos Indicadores de IRAS e RM \u20132023. [Internet]. https:\/\/app.powerbi.com\/view?r=eyJrIjoiOTE3M2RhODAtN2M1Yi00YTc0LWJmMWYtMzNlY2RiZGNlMmNhIiwidCI6ImI2N2FmMjNmLWMzZjMtNGQzNS04MGM3LWI3MDg1ZjVlZGQ4MSJ9 [cited 2025 Mar 17]."},{"key":"10.1016\/j.bjid.2025.104589_bib0002","article-title":"World Health Organization priority antimicrobial resistance in and healthcare-associated bloodstream infections in Brazil (ASCENSION): a prospective, multicentre, observational study","volume":"43","author":"Antochevis","year":"2025","journal-title":"Lancet Reg Health Am"},{"key":"10.1016\/j.bjid.2025.104589_bib0003","unstructured":"[No title]. https:\/\/www.gov.br\/anvisa\/pt-br\/centraisdeconteudo\/publicacoes\/servicosdesaude\/notas-tecnicas\/notas-tecnicas-vigentes\/nota-tecnica-no-74-2022-cglab-daevs-svs-ms [accessed 2025 Mar 17]."},{"key":"10.1016\/j.bjid.2025.104589_bib0004","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"ESCMID guidelines for the treatment of infections caused by multidrug-resistant gram-negative bacilli (endorsed by European Society of Intensive Care Medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.bjid.2025.104589_bib0005","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious diseases society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bjid.2025.104589_bib0006","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jmii.2022.02.001","article-title":"Recommendations and guidelines for the treatment of infections due to multidrug resistant organisms","volume":"55","author":"Sy","year":"2022","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.bjid.2025.104589_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106611","volume":"60","author":"Tiseo","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.bjid.2025.104589_bib0008","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.eimc.2022.06.004","article-title":"Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) on the diagnosis and antimicrobial treatment of infections due to carbapenem-resistant gram-negative bacteria","volume":"41","author":"Pintado","year":"2023","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"4","key":"10.1016\/j.bjid.2025.104589_bib0009","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jmii.2023.01.017","article-title":"Guidelines for the diagnosis, treatment, prevention and control of infections caused by carbapenem-resistant gram-negative bacilli","volume":"56","author":"Zeng","year":"2023","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.bjid.2025.104589_bib0010","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1080\/14787210.2024.2360116","article-title":"Indian consensus on the management of carbapenem-resistant Enterobacterales infection in critically ill patients II (ICONIC II)","volume":"22","author":"Soman","year":"2024","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.bjid.2025.104589_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2024.107186","article-title":"Treatment of infections caused by multidrug-resistant gram-negative bacilli: a practical approach by the Italian (SIMIT) and French (SPILF) Societies of Infectious Diseases","volume":"64","author":"Meschiari","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.bjid.2025.104589_bib0012","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S1473-3099(25)00118-5","article-title":"The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance","volume":"25","author":"Sati","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.bjid.2025.104589_bib0013","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrmicro3432","article-title":"Urinary tract infections: epidemiology, mechanisms of infection and treatment options","volume":"13","author":"Flores-Mireles","year":"2015","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.bjid.2025.104589_bib0014","unstructured":"Urological infections. https:\/\/uroweb.org\/guidelines\/urological-infections\/chapter\/the-guideline [accessed 2025 March 17]."},{"key":"10.1016\/j.bjid.2025.104589_bib0015","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.cmi.2022.08.024","article-title":"Short-course antibiotics for common infections: what do we know and where do we go from here?","volume":"29","author":"Lee","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.bjid.2025.104589_bib0016","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/QCO.0000000000000861","article-title":"Duration of antibiotic therapy in gram-negative infections with a particular focus on multidrug-resistant pathogens","volume":"35","author":"Haddad","year":"2022","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.bjid.2025.104589_bib0017","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S2213-2600(23)00418-6","article-title":"Individualized, short-course antibiotic treatment versus usual long-course treatment for ventilator-associated pneumonia (REGARD-VAP): a multicentre, individually randomised, open-label, non-inferiority trial","volume":"12","author":"Mo","year":"2024","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.bjid.2025.104589_bib0018","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1186\/s13054-024-05178-6","article-title":"Seven versus 14 days of antimicrobial therapy for severe multidrug-resistant gram-negative bacterial infections in intensive care unit patients (OPTIMISE): a randomized, open-label, non-inferiority clinical trial","volume":"28","author":"Arns","year":"2024","journal-title":"Crit Care"},{"key":"10.1016\/j.bjid.2025.104589_bib0019","unstructured":"BrCAST \u2013 Brazilian Committee on Antimicrobial Susceptibility Testing. https:\/\/brcast.org.br\/[accessed 2025 March 17]."},{"key":"10.1016\/j.bjid.2025.104589_bib0020","unstructured":"Minist\u00e9rio da Sa\u00fade. https:\/\/bvs.saude.gov.br\/bvs\/saudelegis\/svs\/2018\/prt0064_14_12_2018.html [accessed 2025 March 17]."},{"key":"10.1016\/j.bjid.2025.104589_bib0021","unstructured":"ESCMID-European society of clinical microbiology, Dis I. EUCAST. https:\/\/www.eucast.org\/[accessed 2025 March 18]."},{"issue":"Suppl 1","key":"10.1016\/j.bjid.2025.104589_bib0022","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1093\/cid\/ciad260","article-title":"A 7-year Brazilian national perspective on plasmid-mediated carbapenem resistance in enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii complex and the impact of the Coronavirus Disease 2019 pandemic on their occurrence","volume":"77","author":"Kiffer","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.bjid.2025.104589_bib0023","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bjm.2016.10.002","article-title":"Antimicrobial resistance in Enterobacteriaceae in Brazil: focus on \u03b2-lactams and polymyxins","volume":"47","author":"Sampaio","year":"2016","journal-title":"Braz J Microbiol"},{"key":"10.1016\/j.bjid.2025.104589_bib0024","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1007\/s10096-017-3012-x","article-title":"Dissemination of bla gene among several Enterobacteriaceae species in Brazil","volume":"36","author":"Magagnin","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"Suppl 2","key":"10.1016\/j.bjid.2025.104589_bib0025","doi-asserted-by":"crossref","first-page":"S166","DOI":"10.1093\/cid\/ciad109","article-title":"Global epidemiology and mechanisms of resistance of Acinetobacter baumannii-calcoaceticus complex","volume":"76","author":"Castanheira","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bjid.2025.104589_bib0026","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.diagmicrobio.2015.08.006","article-title":"The changing epidemiology of Acinetobacter spp. Producing OXA carbapenemases causing bloodstream infections in Brazil: a BrasNet report","volume":"83","author":"Vasconcelos","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.bjid.2025.104589_bib0027","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1586\/eri.09.108","article-title":"Multidrug-resistant pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy","volume":"8","author":"Zavascki","year":"2010","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.bjid.2025.104589_bib0028","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/14787210.2020.1730178","article-title":"Mechanisms of antimicrobial resistance in: a review of current knowledge","volume":"18","author":"Gil-Gil","year":"2020","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.bjid.2025.104589_bib0029","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1128\/AAC.48.2.666-669.2004","article-title":"Class 1 integrons increase trimethoprim-sulfamethoxazole MICs against epidemiologically unrelated Stenotrophomonas maltophilia isolates","volume":"48","author":"Barbolla","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2025.104589_bib0030","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.drup.2016.07.003","article-title":"Antibiotic resistance in Burkholderia species","volume":"28","author":"Rhodes","year":"2016","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.bjid.2025.104589_bib0031","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00920-21","article-title":"Conservation of resistance-nodulation-cell division efflux pump-mediated antibiotic resistance in Burkholderia cepacia Complex and Burkholderia pseudomallei Complex species","volume":"65","author":"Somprasong","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2025.104589_bib0032","doi-asserted-by":"crossref","first-page":"dlab092","DOI":"10.1093\/jacamr\/dlab092","article-title":"Extended-spectrum \u03b2-lactamases: an update on their characteristics, epidemiology and detection","volume":"3","author":"Castanheira","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.bjid.2025.104589_bib0033","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1128\/CMR.00036-08","article-title":"AmpC beta-lactamases","volume":"22","author":"Jacoby","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.bjid.2025.104589_bib0034","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s15010-019-01291-9","article-title":"AmpC \u03b2-lactamase-producing enterobacterales: what a clinician should know","volume":"47","author":"Meini","year":"2019","journal-title":"Infection"},{"key":"10.1016\/j.bjid.2025.104589_bib0035","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00054-22","article-title":"Laboratory detection of carbapenemases among gram-negative organisms","volume":"37","author":"Simner","year":"2024","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.bjid.2025.104589_bib0036","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.01255-23","article-title":"Improved Blue Carba test and Carba NP test for detection and classification of major class A and B carbapenemases, including dual producers, among gram-negative bacilli","volume":"62","author":"Maccari","year":"2024","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.bjid.2025.104589_bib0037","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s42770-022-00857-4","article-title":"Evaluation of phenotypic detection of carbapenemase-producing Pseudomonas spp. From clinical isolates","volume":"54","author":"de Oliveira Santos","year":"2023","journal-title":"Braz J Microbiol"},{"key":"10.1016\/j.bjid.2025.104589_bib0038","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jgar.2024.06.007","article-title":"Susceptibility evaluation of novel beta-lactam\/beta-lactamase inhibitor combinations against carbapenem-resistant Klebsiella pneumoniae from bloodstream infections in hospitalized patients in Brazil","volume":"38","author":"Wilhelm","year":"2024","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.bjid.2025.104589_bib0039","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1007\/s15010-024-02277-y","article-title":"Ceftazidime-avibactam combination therapy versus monotherapy for treating carbapenem-resistant gram-negative infection: a systemic review and meta-analysis","volume":"52","author":"Hsu","year":"2024","journal-title":"Infection"},{"key":"10.1016\/j.bjid.2025.104589_bib0040","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.cmi.2024.11.006","article-title":"Aztreonam and avibactam combination therapy for metallo-\u03b2-lactamase-producing gram-negative bacteria: a comprehensive review","volume":"31","author":"Sangiorgio","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.bjid.2025.104589_bib0041","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00693-24","article-title":"Multicenter evaluation of activity of aztreonam in combination with avibactam, relebactam, and vaborbactam against metallo-\u03b2-lactamase-producing carbapenem-resistant gram-negative bacilli","volume":"68","author":"Tao","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2025.104589_bib0042","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3390\/ph17030383","article-title":"Aztreonam combinations with Avibactam, Relebactam, and Vaborbactam as treatment for New Delhi metallo-\u03b2-lactamase-producing enterobacterales infections-In vitro susceptibility testing","volume":"17","author":"Brauncajs","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.bjid.2025.104589_bib0043","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1007\/s10096-021-04197-3","article-title":"Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam in combination with aztreonam against multidrug-resistant, metallo-\u03b2-lactamase-producing Klebsiella pneumoniae","volume":"40","author":"Maraki","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.bjid.2025.104589_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2022.115674","article-title":"Aztreonam in combination with imipenem-relebactam against clinical and isogenic strains of serine and metallo-\u03b2-lactamase-producing enterobacterales","volume":"103","author":"Biagi","year":"2022","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.bjid.2025.104589_bib0045","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s00134-010-2105-0","article-title":"Optimization of meropenem dosage in the critically ill population based on renal function","volume":"37","author":"Crandon","year":"2011","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.bjid.2025.104589_bib0046","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1128\/AAC.04166-14","article-title":"Population pharmacokinetics and Monte Carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care units","volume":"59","author":"Jaruratanasirikul","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2025.104589_bib0047","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/FTD.0000000000000323","article-title":"A nonparametric pharmacokinetic approach to determine the optimal dosing regimen for 30-minute and 3-hour meropenem infusions in critically ill patients","volume":"38","author":"Mathew","year":"2016","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.bjid.2025.104589_bib0048","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/jac\/dkp139","article-title":"Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution","volume":"64","author":"Roberts","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bjid.2025.104589_bib0049","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02388-19","article-title":"Pharmacodynamics of Meropenem against Acinetobacter baumannii in a neutropenic mouse thigh infection model","volume":"64","author":"Sabet","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2025.104589_bib0050","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1473-3099(18)30099-9","article-title":"Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant gram-negative bacteria: an open-label, randomised controlled trial","volume":"18","author":"Paul","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.bjid.2025.104589_bib0051","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200131","article-title":"Colistin monotherapy versus combination therapy for carbapenem-resistant organisms","volume":"2","author":"Kaye","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.bjid.2025.104589_bib0052","unstructured":"0002_USCAST_aminoglycoside_1.3_24feb19_Final_revised_v2.pdf. Available at: https:\/\/app.box.com\/s\/1hxc8inf8u3rranwmk3efx48upvwt0ww [accessed May 4, 2025]."},{"key":"10.1016\/j.bjid.2025.104589_bib0053","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1128\/JCM.44.3.1101-1104.2006","article-title":"Accuracy of three automated systems (MicroScan WalkAway, VITEK, and VITEK 2) for susceptibility testing of Pseudomonas aeruginosa against five broad-spectrum beta-lactam agents","volume":"44","author":"Sader","year":"2006","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.bjid.2025.104589_bib0054","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/jac\/dkaa396","article-title":"Molecular mechanisms driving the in vivo development of OXA-10-mediated resistance to ceftolozane\/tazobactam and ceftazidime\/avibactam during treatment of XDR Pseudomonas aeruginosa infections","volume":"76","author":"Arca-Su\u00e1rez","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bjid.2025.104589_bib0055","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02165-19","article-title":"Activity of Imipenem-Relebactam against a large collection of Pseudomonas aeruginosa clinical isolates and isogenic \u03b2-lactam-resistant mutants","volume":"64","author":"Fraile-Ribot","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2025.104589_bib0056","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.cmi.2023.12.026","article-title":"Pseudomonas aeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID\/ISARPAE Group","volume":"30","author":"Oliver","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.bjid.2025.104589_bib0057","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jac\/dkaf083","article-title":"Ceftazidime-avibactam plus aztreonam cocktail for the treatment of VIM-producing Pseudomonas aeruginosa infections: good enough to have another?","volume":"80","author":"Pina-S\u00e1nchez","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bjid.2025.104589_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2025.03.013","article-title":"Emerging resistance mechanisms to newer \u03b2-lactams in Pseudomonas aeruginosa","author":"Oliver","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.bjid.2025.104589_bib0059","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1093\/jac\/dkac184","article-title":"Ceftolozane\/tazobactam for hospital-acquired\/ventilator-associated bacterial pneumonia due to ESBL-producing enterobacterales: a subgroup analysis of the ASPECT-NP clinical trial","volume":"77","author":"Paterson","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bjid.2025.104589_bib0060","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/jac\/dkm193","article-title":"Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials","volume":"60","author":"Vidal","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bjid.2025.104589_bib0061","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/cid\/ciae328","article-title":"Piperacillin\/tazobactam Susceptibility test interpretive criteria for enterobacterales: recommendations from the United States committee on antimicrobial susceptibility testing","volume":"79","author":"Lodise","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bjid.2025.104589_bib0062","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.diagmicrobio.2003.11.007","article-title":"In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae","volume":"49","author":"Burgess","year":"2004","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.bjid.2025.104589_bib0063","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1055\/s-0034-1398387","article-title":"Clinical management of infections caused by Enterobacteriaceae that express extended-spectrum \u03b2-lactamase and AmpC enzymes","volume":"36","author":"Harris","year":"2015","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.bjid.2025.104589_bib0064","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/23744235.2024.2324365","article-title":"Risk factors for mortality in bacteremia - a meta-analysis","volume":"56","author":"Huang","year":"2024","journal-title":"Infect Dis (Lond)"},{"key":"10.1016\/j.bjid.2025.104589_bib0065","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1007\/s10096-020-03960-2","article-title":"Management and outcomes of Burkholderia cepacia complex bacteremia in patients without cystic fibrosis: a retrospective observational study","volume":"39","author":"Lee","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.bjid.2025.104589_bib0066","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jhin.2013.06.013","article-title":"Characteristics and outcome predictors of patients involved in an outbreak of Burkholderia cepacia complex","volume":"85","author":"Righi","year":"2013","journal-title":"J Hosp Infect"},{"key":"10.1016\/j.bjid.2025.104589_bib0067","article-title":"Epidemiology, microbiological, clinical characteristics, and outcome of complex infections in non-cystic fibrosis adult patients from Qatar","volume":"11","author":"Ibrahim","year":"2024","journal-title":"IJID Reg"},{"key":"10.1016\/j.bjid.2025.104589_bib0068","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/cid\/cix559","article-title":"A 17-year nationwide study of Burkholderia cepacia complex bloodstream infections among patients in the United States Veterans Health Administration","volume":"65","author":"El Chakhtoura","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bjid.2025.104589_bib0069","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3109\/00365548.2011.589076","article-title":"Risk factors for mortality in patients with Burkholderia cepacia complex bacteraemia","volume":"43","author":"Ku","year":"2011","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.bjid.2025.104589_bib0070","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.diagmicrobio.2016.08.015","article-title":"In vitro susceptibility of Burkholderia cepacia complex isolates: comparison of disk diffusion, etest\u00ae, agar dilution, and broth microdilution methods","volume":"86","author":"Fehlberg","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.bjid.2025.104589_bib0071","article-title":"Evaluation of susceptibility testing methods for Burkholderia cepacia complex: a comparison of broth microdilution, agar dilution, gradient strip and EUCAST disc diffusion","author":"Wootton","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.bjid.2025.104589_bib0072","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00590-18","article-title":"Susceptibility of Burkholderia cepacia Complex isolated from cystic fibrosis patients to Ceftazidime-Avibactam and Ceftolozane-Tazobactam","volume":"62","author":"Van Dalem","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2025.104589_bib0073","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1093\/jac\/dkq306","article-title":"In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters","volume":"65","author":"Mushtaq","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bjid.2025.104589_bib0074","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1021\/acsinfecdis.7b00020","article-title":"Overcoming an extremely drug resistant (XDR) pathogen: avibactam restores susceptibility to ceftazidime for Burkholderia cepacia complex isolates from cystic fibrosis patients","volume":"3","author":"Papp-Wallace","year":"2017","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.bjid.2025.104589_bib0075","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/phar.2209","volume":"39","author":"Tsuji","year":"2019","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.bjid.2025.104589_bib0076","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s12028-016-0269-3","article-title":"Systematic review of efficacy, pharmacokinetics, and administration of intraventricular aminoglycosides in adults","volume":"25","author":"LeBras","year":"2016","journal-title":"Neurocrit Care"},{"key":"10.1016\/j.bjid.2025.104589_bib0077","article-title":"Intravenous plus intraventricular tigecycline-amikacin therapy for the treatment of carbapenem-resistant Klebsiella pneumoniae ventriculitis: a case report","volume":"101","author":"Li","year":"2022","journal-title":"Medicine"},{"issue":"3","key":"10.1016\/j.bjid.2025.104589_bib78","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01268-16","article-title":"High-dose ampicillin-sulbactam combinations combat polymyxin-resistant Acinetobacter baumannii in a hollow-fiber infection model","volume":"61","author":"Lenhard","year":"2017","journal-title":"Antimicrob Agents Chemother"}],"container-title":["The Brazilian Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S141386702500090X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S141386702500090X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T21:29:43Z","timestamp":1764624583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S141386702500090X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":78,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S141386702500090X"],"URL":"https:\/\/doi.org\/10.1016\/j.bjid.2025.104589","relation":{},"ISSN":["1413-8670"],"issn-type":[{"value":"1413-8670","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Guideline for antimicrobial treatment of multidrug-resistant Gram-negative infections: practice recommendations of the Brazilian Society of Infectious Diseases","name":"articletitle","label":"Article Title"},{"value":"The Brazilian Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bjid.2025.104589","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Sociedade Brasileira de Infectologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"104589"}}